Neoplasms, Plasma Cell: all 2,314 studies

Page 8 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.

• A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple MyelomaCompletedNCT00722566Phase 3Results posted
• Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal FunctionCompletedNCT00721734Phase 2Results posted
• Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00719901Phase 1/2Results posted
• Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other DiseaseTerminatedNCT00719849Phase 2Results posted
• American Ginseng in Treating Patients With Fatigue Caused by CancerCompletedNCT00719563Phase 3Results posted
• An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney FunctionTerminatedNCT00718640Phase 2Results posted
• A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple MyelomaCompletedNCT00718419Phase 2Results posted
• Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)CompletedNCT00701103Phase 1Results posted
• Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance TherapyCompletedNCT00691704Phase 2Results posted
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantCompletedNCT00691015Phase 2Results posted
• Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple MyelomaCompletedNCT00689936Phase 3Results posted
• Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00687674Phase 1Results posted
• Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior TreatmentCompletedNCT00670631Phase 2Results posted
• Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer PainCompletedNCT00666211Phase 3Results posted
• Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerCompletedNCT00661999Phase 3Results posted
• Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma PatientsCompletedNCT00661544Phase 1/2Results posted
• Preemptive Strike With Bortezomib in Multiple Myeloma PatientsTerminatedNCT00657553Phase 3Results posted
• ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of PainCompletedNCT00656305Not applicableResults posted
• Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom BurdenCompletedNCT00651937Phase 2Results posted
• Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MMTerminatedNCT00648739Phase 1/2Results posted
• Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)CompletedNCT00642954Phase 1Results posted
• A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple MyelomaCompletedNCT00639002Phase 2Results posted
• Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple MyelomaCompletedNCT00635154Phase 2Results posted
• Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00635024Phase 2Results posted
• Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma ParticipantsCompletedNCT00622505Phase 4Results posted
• A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple MyelomaCompletedNCT00622336Phase 3Results posted
• Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell TransplantCompletedNCT00619684Phase 2Results posted
• Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic CancersCompletedNCT00619645Phase 2Results posted
• Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)CompletedNCT00617591Phase 2Results posted
• Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning RegimenTerminatedNCT00615589Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaCompletedNCT00612716Phase 2Results posted
• Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic CancerCompletedNCT00611351Phase 2Results posted
• Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00609167Phase 2Results posted
• Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate MofetilTerminatedNCT00608517Not applicableResults posted
• Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple MyelomaCompletedNCT00603447Phase 1Results posted
• Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell TransplantTerminatedNCT00602446Phase 2Results posted
• Multi-day Doses in Prevention of Nausea and EmesisCompletedNCT00600353Phase 2Results posted
• T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other DiseasesTerminatedNCT00589602Phase 2Results posted
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological CancerCompletedNCT00589563Phase 2Results posted
• Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple MyelomaCompletedNCT00581919Phase 2Results posted
• UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple MyelomaCompletedNCT00580372Phase 2Results posted
• Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)TerminatedNCT00579111Phase 1/2Results posted
• Bone Marker Assessment of Multiple Myeloma Patients Treated With AminobisphosphonatesCompletedNCT00577642Phase 2Results posted
• 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACECompletedNCT00577512Phase 2Results posted
• Effects of Exercise in Combination With Epoetin AlfaCompletedNCT00577096Not applicableResults posted
• Daratumumab (HuMax®-CD38) Safety Study in Multiple MyelomaCompletedNCT00574288Phase 2Results posted
• UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and ThalidomideTerminatedNCT00574080Phase 3Results posted
• Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2TerminatedNCT00573391Phase 3Results posted
• UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00569868Not applicableResults posted
• Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk LymphomaCompletedNCT00569309Not applicableResults posted
• Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple MyelomaTerminatedNCT00567229Phase 2Results posted
• Activated White Blood Cells With ASCT for Newly Diagnosed Multiple MyelomaCompletedNCT00566098Phase 1/2Results posted
• Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00564889Phase 2Results posted
• Dasatinib in Combination With Revlimid (and Dexamethasone)CompletedNCT00560391Phase 1Results posted
• Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple MyelomaTerminatedNCT00560352Phase 1Results posted
• CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or AmyloidosisCompletedNCT00558896Phase 2Results posted
• An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.CompletedNCT00555906Phase 2Results posted
• An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple MyelomaCompletedNCT00552396Phase 1Results posted
• Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart DysfunctionCompletedNCT00547365Phase 1/2Results posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
• Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00540644Phase 2Results posted
• Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple MyelomaTerminatedNCT00538824Phase 2Results posted
• Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple MyelomaCompletedNCT00538733Phase 2Results posted
• High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00536601Not applicableResults posted
• Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma PatientsCompletedNCT00536575Phase 1/2Results posted
• Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell TransplantCompletedNCT00534118Not applicableResults posted
• A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple MyelomaCompletedNCT00531453Phase 2Results posted
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaCompletedNCT00531284Phase 1/2Results posted
• Phase 2 Study of Carfilzomib in Relapsed Multiple MyelomaCompletedNCT00530816Phase 2Results posted
• Dalteparin in Preventing DVT in Participants With CancerCompletedNCT00525057Not applicableResults posted
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple MyelomaCompletedNCT00523848Phase 2Results posted
• Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With DexamethasoneTerminatedNCT00522392Phase 3Results posted
• Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With CancerCompletedNCT00516503Phase 3Results posted
• Sunitinib in Treating Patients With Relapsed Multiple MyelomaCompletedNCT00514137Phase 2Results posted
• Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell TransplantCompletedNCT00513474Phase 1Results posted
• Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple MyelomaCompletedNCT00511238Phase 2Results posted
• Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma PatientsCompletedNCT00507442Phase 1/2Results posted
• Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and PrednisoneCompletedNCT00507416Phase 3Results posted
• FM 140 vs FM100 Study in Patients With Multiple MyelomaCompletedNCT00505895Phase 2Results posted
• Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple MyelomaCompletedNCT00483262Phase 1/2Results posted
• A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00478777Phase 3Results posted
• Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00478218Phase 2Results posted
• Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00477971Phase 3Results posted
• Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00477750Phase 1/2Results posted
• Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCompletedNCT00474929Phase 1/2Results posted
• A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)CompletedNCT00473590Phase 2Results posted
• Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple MyelomaTerminatedNCT00470093Early Phase 1Results posted
• Velcade, Trisenox, Vitamin C and Melphalan for Myeloma PatientsCompletedNCT00469209Phase 1/2Results posted
• A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00464178Phase 2Results posted
• Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple MyelomaCompletedNCT00461045Phase 2Results posted
• Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic AmyloidosisCompletedNCT00458822Phase 2Results posted
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple MyelomaCompletedNCT00458705Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseasesCompletedNCT00453206Not applicableResults posted
• Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple MyelomaCompletedNCT00450814Phase 1/2Results posted
• Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based RegimenCompletedNCT00448357Phase 1/2Results posted
• Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseCompletedNCT00448201Phase 2Results posted
• Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple MyelomaCompletedNCT00445692Phase 2Results posted
• Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00445484Phase 2Results posted
• Efficacy and Safety of LBH589B in Adult Patients With Multiple MyelomaTerminatedNCT00445068Phase 2Results posted
• Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple MyelomaTerminatedNCT00441168Phase 2Results posted

← Neoplasms, Plasma Cell overview